In short
CDR132L is an innovative drug currently being studied in clinical trials for its potential to treat various forms of heart failure. This synthetic antisense oligonucleotide (ASO) works by inhibiting microRNA-132-3p (miR-132), which plays a crucial role in cardiac remodeling and heart failure progression. The ongoing trials aim to assess the safety, efficacy, and pharmacological properties of CDR132L in patients with different types of heart conditions, including those who have recently experienced a heart attack or have stable heart failure.
At a glance
- Drug Name
- CDR132L
- Drug Type
- Synthetic antisense oligonucleotide (ASO)
- Mechanism of Action
- Selective inhibitor of microRNA-132-3p (miR-132)
- Target Conditions
- Acute myocardial infarction, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
- Administration
- Intravenous injection
- Clinical Trial Phases
- Phase 1 and Phase 2
- Primary Outcomes
- Safety, efficacy in improving heart function, changes in cardiac structure
- Key Measurements
- Left ventricular volume, left ventricular mass, biomarker levels, cardiac imaging results
What is CDR132L?
CDR132L is a new medication being developed to treat various heart conditions. It is classified as a synthetic antisense oligonucleotide (ASO), which is a type of drug that can influence how genes work in our body. Specifically, CDR132L is designed to selectively inhibit (or block) a molecule called microRNA-132-3p (miR-132).
How CDR132L Works
CDR132L works by targeting a specific molecule in heart cells called miR-132. This molecule acts as a central switch that affects how certain genes behave in the heart. These genes are involved in processes that can lead to unhealthy changes in the heart's structure and function, particularly after a heart attack or in cases of heart failure.
By inhibiting miR-132, CDR132L aims to:
- Prevent or reverse harmful changes in the heart's structure (called "cardiac remodeling")
- Reduce abnormal growth of heart muscle cells (called "hypertrophy")
- Improve the heart's ability to pump blood effectively
Conditions Treated by CDR132L
CDR132L is being studied for several heart-related conditions:
- Heart Failure after Heart Attack: For patients who have reduced heart function (measured as Left Ventricular Ejection Fraction or LVEF) after experiencing a heart attack (myocardial infarction).
- Heart Failure with Preserved Ejection Fraction (HFpEF): This is a type of heart failure where the heart's pumping ability is normal or near-normal, but it has trouble filling with blood.
- Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): This is a condition where the heart's pumping ability is slightly reduced.
- Stable Heart Failure of Ischemic Origin: This refers to heart failure caused by reduced blood flow to the heart, typically due to coronary artery disease.
Clinical Trials of CDR132L
CDR132L is currently being tested in several clinical trials:
- Phase 2 Trial for Heart Failure after Heart Attack: This study is testing two different doses of CDR132L in patients who have reduced heart function after a heart attack. The main goal is to see if CDR132L can improve heart function and reduce the size of the heart's left ventricle.
- Phase 2 Trial for HFpEF and HFmrEF: This study is looking at how CDR132L affects the structure and function of the heart in patients with preserved or mildly reduced heart function. It's measuring things like heart muscle mass, the size of the heart's chambers, and how well the heart relaxes and fills with blood.
- Phase 1 Trial for Stable Heart Failure: This early-stage trial is primarily focused on assessing the safety of CDR132L and how it's processed by the body (pharmacokinetics) in patients with stable heart failure.
How CDR132L is Administered
In the clinical trials, CDR132L is being given as an intravenous (IV) injection. This means it's delivered directly into a vein. The dosing schedule varies depending on the specific trial:
- In some trials, it's given as a single dose on specific days (like Day 1, Day 29, and Day 57).
- In others, it's administered six times over the course of the study.
The exact dose is often calculated based on the patient's body weight.
Safety and Side Effects
As CDR132L is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring for any side effects or adverse events that may occur. One of the primary goals of these trials, especially the Phase 1 study, is to assess the safety and tolerability of CDR132L.
It's important to note that in clinical trials, some patients receive a placebo (a harmless substance with no active ingredients) instead of the actual drug. This helps researchers accurately determine the effects of the medication being studied.